Collectively, our findings reveal the pivotal role of ZFP36 in mediating VSMC function and maintaining vascular homeostasis, and thereby expand the therapeutic usage of Dex, offering a novel strategy for AAA treatment. Here, ZFP36 is linked to triple-A syndrome.